SIGILON THERAPEUTICS INC (SGTX) Stock Price, Quote, News and Overview
NASDAQ:SGTX - Nasdaq - US82657L2060 - Common Stock - Currency: USD
SGTX Quote, Performance and Key Statistics
22.47
-0.59 (-2.56%)
The current stock price of SGTX is 22.47 USD. In the past month the price increased by 4.95%. In the past year, price increased by 136.78%.
SGTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.97 | 326.55B | ||
| AMGN | AMGEN INC | 12.81 | 142.94B | ||
| GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
| ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
| ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
| NTRA | NATERA INC | N/A | 20.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
| BIIB | BIOGEN INC | 7.47 | 17.32B |
Related stock screener links
About SGTX
Company Profile
Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2020-12-04. The firm is focused on developing functional cures for patients with acute and chronic diseases by providing stable and durable levels of therapeutic molecules to patients. The Company’s Shielded Living Therapeutics (SLTx) platform is comprised of two primary elements: the cells and the sphere. The Company’s lead product candidate, SIG-002, is designed to replace islet cells for the treatment of Type 1 Diabetes (T1D). The company is also developing product candidates for the treatment of lysosomal diseases. Its program for diabetes, it focused to apply the SLTx platform to develop product candidates, including product candidates for patients with liver and immune mediated diseases, and explore delivery of different molecules and alternative routes of administration. The company also engineers cells to express a therapeutic molecule of choice in a continuous manner, which it refers to as constitutive expression.
Company Info
SIGILON THERAPEUTICS INC
100 Binney Street, Ste 600
Cambridge MASSACHUSETTS US
Employees: 62
Phone: 16173367540.0
SIGILON THERAPEUTICS INC / SGTX FAQ
What is the stock price of SIGILON THERAPEUTICS INC today?
The current stock price of SGTX is 22.47 USD. The price decreased by -2.56% in the last trading session.
What is the ticker symbol for SIGILON THERAPEUTICS INC stock?
The exchange symbol of SIGILON THERAPEUTICS INC is SGTX and it is listed on the Nasdaq exchange.
On which exchange is SGTX stock listed?
SGTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SIGILON THERAPEUTICS INC stock?
9 analysts have analysed SGTX and the average price target is 48.28 USD. This implies a price increase of 114.86% is expected in the next year compared to the current price of 22.47. Check the SIGILON THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SIGILON THERAPEUTICS INC worth?
SIGILON THERAPEUTICS INC (SGTX) has a market capitalization of 56.50M USD. This makes SGTX a Micro Cap stock.
How many employees does SIGILON THERAPEUTICS INC have?
SIGILON THERAPEUTICS INC (SGTX) currently has 62 employees.
What are the support and resistance levels for SIGILON THERAPEUTICS INC (SGTX) stock?
SIGILON THERAPEUTICS INC (SGTX) has a support level at 21.18 and a resistance level at 22.51. Check the full technical report for a detailed analysis of SGTX support and resistance levels.
Is SIGILON THERAPEUTICS INC (SGTX) expected to grow?
The Revenue of SIGILON THERAPEUTICS INC (SGTX) is expected to grow by 19.62% in the next year. Check the estimates tab for more information on the SGTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SIGILON THERAPEUTICS INC (SGTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SGTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SGTX, evaluating the profitability, health, valuation and growth aspects
- SIGILON THERAPEUTICS INC (SGTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SIGILON THERAPEUTICS INC (SGTX) Sales and EPS estimates to see what analysts future expectations are.
- SIGILON THERAPEUTICS INC (SGTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SIGILON THERAPEUTICS INC (SGTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SIGILON THERAPEUTICS INC (SGTX) Stock Chart to make your own analysis
- SIGILON THERAPEUTICS INC (SGTX) Latest news and press-releases to stay up to date.
Does SIGILON THERAPEUTICS INC (SGTX) stock pay dividends?
SGTX does not pay a dividend.
When does SIGILON THERAPEUTICS INC (SGTX) report earnings?
SIGILON THERAPEUTICS INC (SGTX) will report earnings on 2023-11-08, after the market close.
What is the Price/Earnings (PE) ratio of SIGILON THERAPEUTICS INC (SGTX)?
SIGILON THERAPEUTICS INC (SGTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.67).
SGTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SGTX. When comparing the yearly performance of all stocks, SGTX is one of the better performing stocks in the market, outperforming 99.58% of all stocks.
SGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SGTX. SGTX has a bad profitability rating. Also its financial health evaluation is rather negative.
SGTX Financial Highlights
Over the last trailing twelve months SGTX reported a non-GAAP Earnings per Share(EPS) of -9.67. The EPS decreased by -327.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.31 |
SGTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to SGTX. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -34.47% and a revenue growth 19.62% for SGTX